

One Hundred Fourteenth Congress  
of the  
United States of America

AT THE SECOND SESSION

*Begun and held at the City of Washington on Monday,  
the fourth day of January, two thousand and sixteen*

An Act

To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

*Be it enacted by the Senate and House of Representatives of  
the United States of America in Congress assembled,*

**SECTION 1. SHORT TITLE.**

This Act may be cited as the “Adding Zika Virus to the FDA Priority Review Voucher Program Act”.

**SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW  
VOUCHER PROGRAM TO ENCOURAGE TREATMENTS FOR  
ZIKA VIRUS DISEASE.**

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

- (1) by redesignating subparagraph (R) as subparagraph (S);
- (2) in subparagraph (Q), by striking “Filoviruses” and inserting “Filovirus Diseases”; and
- (3) by inserting after subparagraph (Q) the following:  
“(R) Zika Virus Disease.”.

*Speaker of the House of Representatives.*

*Vice President of the United States and  
President of the Senate.*